Albireo licenses Ajinomoto Asian rights to GI therapeutic elobixibat
Swedish GI drug developer Albireo AB has licensed public Japanese pharmaco Ajinomoto Co. Inc. exclusive rights to develop and commercialize elobixibat in Japan, South Korea, Thailand, Indonesia, Vietnam, and Taiwan.
- Specialty Pharmaceuticals
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com